×
CSL Long Term Debt 2017-2024 | CSLLY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CSL long term debt for the quarter ending December 31, 2024 was
$11.239B
, a
116.26% increase
year-over-year.
CSL long term debt for 2024 was
$11.239B
, a
0.6% increase
from 2023.
CSL long term debt for 2023 was
$11.172B
, a
116.3% increase
from 2022.
CSL long term debt for 2022 was
$5.165B
, a
3.15% decline
from 2021.
View More
CSL Long Term Debt 2017-2024 | CSLLY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CSL long term debt for 2024 was
$11.239B
, a
0.6% increase
from 2023.
CSL long term debt for 2023 was
$11.172B
, a
116.3% increase
from 2022.
CSL long term debt for 2022 was
$5.165B
, a
3.15% decline
from 2021.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$220.6B
Amgen (AMGN)
$158.8B
Gilead Sciences (GILD)
$136.4B
Vertex Pharmaceuticals (VRTX)
$120.4B
Bristol Myers Squibb (BMY)
$95.4B
GSK (GSK)
$78.4B
Regeneron Pharmaceuticals (REGN)
$61.3B
Alnylam Pharmaceuticals (ALNY)
$41.1B
Argenex SE (ARGX)
$34.3B
BioNTech SE (BNTX)
$27.1B
Royalty Pharma (RPRX)
$20.2B
Biogen (BIIB)
$19.7B
Insmed (INSM)
$18.6B
Illumina (ILMN)
$15.7B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.7B
Incyte (INCY)
$13.3B
Moderna (MRNA)
$13B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.1B
QIAGEN (QGEN)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$9.8B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.5B
Blueprint Medicines (BPMC)
$8.4B
Roivant Sciences (ROIV)
$7.7B
Repligen (RGEN)
$7.3B
Regencell Bioscience Holdings (RGC)
$7.3B